Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 9/2023

27-07-2023 | Urticaria | Disease Management

Consider comorbidities, concomitant medications and organ function when treating chronic urticaria in older adults

Author: Tina Nie

Published in: Drugs & Therapy Perspectives | Issue 9/2023

Login to get access

Abstract

Chronic urticaria in older adults is not well understood and specific guidelines on the diagnosis and treatment of this skin condition in older adults are lacking. Care should be taken in the diagnosis of chronic urticaria in older adults, as they may have different clinical features and relevant differential diagnoses than younger adults. The recommended treatment of chronic urticaria in older adults follows the same guidelines as for the general population. However, the choice of pharmacological treatment in older adults requires special consideration, due to the greater prevalence of comorbidities, concomitant medication use and impaired liver or kidney function in this population.
Literature
1.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–66.CrossRefPubMed
2.
Saini S, Shams M, Bernstein JA, et al. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract. 2020;8(6):1866–74.CrossRefPubMed
3.
Khaliliya R, Confino-Cohen R, Lachover-Roth I, et al. Chronic urticaria in elderly-new insights. J Allergy Clin Immunol Pract. 2023;11(4):1290–4.CrossRefPubMed
4.
Patruno C, Fabbrocini G, Cillo F, et al. Chronic urticaria in older adults: treatment considerations. Drugs Aging. 2023;40(3):165–77.CrossRefPubMed
5.
Magen E, Mishal J, Schlesinger M. Clinical and laboratory features of chronic idiopathic urticaria in the elderly. Int J Dermatol. 2013;52(11):1387–91.CrossRefPubMed
6.
Wertenteil S, Strunk A, Garg A. Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2019;81(1):152–6.CrossRefPubMed
7.
Weller K, Maurer M, Bauer A, et al. Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. J Eur Acad Dermatol Venereol. 2022;36(1):91–9.CrossRefPubMed
8.
Chen YJ, Wu CY, Shen JL, et al. Cancer risk in patients with chronic urticaria: a population-based cohort study. Arch Dermatol. 2012;148(1):103–8.CrossRefPubMed
9.
10.
11.
Dávila I, Cuvillo A, Mullol J, et al. Use of second generation H1 antihistamines in special situations. J Investig Allergol Clin Immunol. 2013;23(Suppl 1):1–16.PubMed
12.
13.
Novartis Pharmaceuticals Corporation. Sandimmune—cyclosporine capsule, liquid filled; cyclosporine injection; cyclosporine solution: US prescribing information. 2023. https://​dailymed.​nlm.​nih.​gov/​. Accessed 12 Jul 2023.
14.
Falck P, Asberg A, Byberg KT, et al. Reduced elimination of cyclosporine A in elderly (65 years) kidney transplant recipients. Transplantation. 2008;86(10):1379–83.CrossRefPubMed
15.
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–35.CrossRefPubMed
16.
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–9.CrossRefPubMed
17.
Martina E, Damiani G, Grieco T, et al. It is never too late to treat chronic spontaneous urticaria with omalizumab: real-life data from a multicenter observational study focusing on elderly patients. Dermatol Ther. 2021;34(2):e14841.CrossRefPubMed
18.
Nettis E, Cegolon L, Leo E, et al. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real-life experience. Ann Allergy Asthma Immunol. 2018;120(3):318–23.CrossRefPubMed
19.
Kitao R, Oda Y, Washio K, et al. Lower efficacy of omalizumab in older adults with chronic spontaneous urticaria. J Dermatol. 2022;49(7):729–31.CrossRefPubMed
Metadata
Title
Consider comorbidities, concomitant medications and organ function when treating chronic urticaria in older adults
Author
Tina Nie
Publication date
27-07-2023
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 9/2023
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-023-01016-x

Other articles of this Issue 9/2023

Drugs & Therapy Perspectives 9/2023 Go to the issue

Drug Reactions and Interactions

First reports of adverse drug reactions

Disease Management

Manage truncal acne and scarring the same as for facial acne, but more trunk-specific therapies are warranted

Adis Drug Q&A

Linzagolix in moderate to severe symptoms of uterine fibroids: a profile of its use

Adis Drug Q&A

Tapinarof cream 1% in plaque psoriasis: a profile of its use

Adis Summary of Research

Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents